Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C3JB
|
|||
Drug Name |
MB-102
|
|||
Synonyms |
Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0
Click to Show/Hide
|
|||
Indication | Acute kidney injury [ICD-11: GB60; ICD-9: 584] | Phase 2 | [1] | |
Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2], [3] | ||
Company |
Mustang Bio New York, NY
|
|||
Structure |
Download2D MOL |
|||
Formula |
C12H16N6O8
|
|||
Canonical SMILES |
C(C(C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)NC(CO)C(=O)O)N)O
|
|||
InChI |
1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
|
|||
InChIKey |
XHNJXRDGTITISI-QWWZWVQMSA-N
|
|||
CAS Number |
CAS 1313706-17-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | CAR-T-Cell-Therapy | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
PI3K-Akt signaling pathway | ||||
Apoptosis | ||||
Jak-STAT signaling pathway | ||||
Hematopoietic cell lineage | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
IL3 Signaling Pathway | ||||
Pathway Interaction Database | IL3-mediated signaling events | |||
Reactome | GPVI-mediated activation cascade | |||
G beta:gamma signalling through PI3Kgamma | ||||
Interleukin-3, 5 and GM-CSF signaling | ||||
RAF/MAP kinase cascade | ||||
Interleukin receptor SHC signaling | ||||
WikiPathways | IL-3 Signaling Pathway | |||
Interleukin-2 signaling | ||||
Interleukin-3, 5 and GM-CSF signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02772276) Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.